Almirall: closes US dermatology deal with Allergan
(CercleFinance.com) - Spain's Almirall has closed the acquisition of Allergan's US medical dermatology portfolio for 550 million dollars, paid in cash, the skin-health focused pharmaceutical firm said on Friday.
The acquired portfolio includes a new drug product and four mature brands that are already marketed, which generated total sales of 70 million dollars over the first six months of 2018.
The promising Seysara, an antibiotic with anti-inflammatory properties for the treatment of acne, is expected to have peak sales of up to 200 million dollars after its anticipated approval in the fourth quarter of 2018.
The agreement also includes a possible earn-out of up to 100 million dollars, payable in 2022.
The transaction was funded through a bridge loan from the banks BBVA and Santander.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The acquired portfolio includes a new drug product and four mature brands that are already marketed, which generated total sales of 70 million dollars over the first six months of 2018.
The promising Seysara, an antibiotic with anti-inflammatory properties for the treatment of acne, is expected to have peak sales of up to 200 million dollars after its anticipated approval in the fourth quarter of 2018.
The agreement also includes a possible earn-out of up to 100 million dollars, payable in 2022.
The transaction was funded through a bridge loan from the banks BBVA and Santander.
Copyright (c) 2018 CercleFinance.com. All rights reserved.